Promising Antileukemic Activity of Bleximenib in Combination Therapy for Acute Myeloid Leukemia

Johnson & Johnson announced positive Phase 1b data for bleximenib, a menin inhibitor, in combination with venetoclax and azacitidine for acute myeloid...
Home/KnloSights/Clinical Trial Updates/Promising Antileukemic Activity of Bleximenib in Combination Therapy for Acute Myeloid Leukemia